We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ARWR market cap is 2.52B. The company's latest EPS is USD -4.8177 and P/E is -4.20.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 16.1M | 3.55M | 0 | 0 | 0 |
| Operating Income | -108.33M | -136.55M | -126.19M | -176.14M | -162.2M |
| Net Income | -109.68M | -132.86M | -125.3M | -170.79M | -170.54M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 87.99M | 138.29M | 243.23M | 240.74M | 3.55M |
| Operating Income | -93.16M | -149.04M | -178.51M | -205M | -601.08M |
| Net Income | -84.55M | -140.85M | -176.06M | -205.28M | -599.49M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 765.55M | 626.29M | 955.15M | 883.76M | 1.14B |
| Total Liabilities | 478.39M | 452.57M | 459.75M | 544.79M | 948.74M |
| Total Equity | 287.16M | 173.71M | 495.41M | 338.97M | 191.06M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 522.5M | 710.15M | 691.94M | 765.55M | 1.14B |
| Total Liabilities | 60.73M | 301.33M | 273.6M | 478.39M | 948.74M |
| Total Equity | 461.78M | 408.82M | 418.34M | 287.16M | 191.06M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -153.89M | -117.84M | -210.22M | -325.64M | -462.85M |
| Investing | -96.16M | 64.84M | -204.1M | -197.15M | -420.07M |
| Financing | 253.05M | 267k | 431.04M | 481.43M | 870.52M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -95.39M | 171.22M | -136.13M | -153.89M | -462.85M |
| Investing | -240.78M | -141.68M | -5.42M | -96.16M | -420.07M |
| Financing | 257.95M | 11.31M | 65.19M | 253.05M | 870.52M |
| Market Cap | 2.52B |
| Price to Earnings Ratio | -4.20 |
| Price to Sales Ratio | 710.53 |
| Price to Cash Ratio | 25.4 |
| Price to Book Ratio | 13.19 |
| Dividend Yield | - |
| Shares Outstanding | 124.43M |
| Average Volume (1 week) | 1.31M |
| Average Volume (1 Month) | 2.71M |
| 52 Week Change | -36.25% |
| 52 Week High | 36.72 |
| 52 Week Low | 17.05 |
| Spread (Intraday) | 1.01 (4.76%) |
| Company Name | Arrowhead Pharmaceuticals Inc |
| Address |
2140 south dupont highway camden, delaware 19934 |
| Website | https://www.arrowheadpharma.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
